Unión Europea - español - EMA (European Medicines Agency)

nova laboratories ireland limited - monohidrato de 6-mercaptopurina - leucemia, linfoide - agentes antineoplásicos - xaluprine está indicado para el tratamiento de la leucemia linfoblástica aguda (lla) en adultos, adolescentes y niños.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zentiva k.s. - sitagliptina hidrocloruro; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/1.000 mg - sitagliptina hidrocloruro 50 mg; metformina hidrocloruro 1000 mg - metformina y sitagliptina

Venezuela - español - Instituto Nacional de Higiene

medley farmaceutica, s.a. - venlafaxina - c - 150 mg

Venezuela - español - Instituto Nacional de Higiene

medley farmaceutica, s.a - venlafaxina - capsulas - 75 mg

Unión Europea - español - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rechazo del injerto - inmunosupresores - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

norbrook laboratories (ireland) limited - marbofloxacino - gotas Óticas en suspensiÓn - - dexametasona y antiinfecciosos - perros

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

norbrook laboratories ltd. - marbofloxacino, clotrimazol, dexametasona - gotas Óticas en suspensiÓn - excipientes: propil galato (e 310), oleato de sorbitan, silice coloidal anhidra, trigliceridos de cadena media - dexametasona y antiinfecciosos - perros

Venezuela - español - Instituto Nacional de Higiene

medley farmaceutica, s.a. - rosuvastatina - comprimido recubierto - 10 mg

Venezuela - español - Instituto Nacional de Higiene

medley farmaceutica, s.a. - rosuvastatina - comprimido recubierto - 20 mg

Venezuela - español - Instituto Nacional de Higiene

medley farmaceutica, s.a. - atorvastatina (atorvastatina calcica) - comprimido recubierto - 10 mg